One of the biggest problems for healthcare firm Johnson & Johnson (NYSE:JNJ) in the last decade or so has been talc. This ...
On April 16, Johnson & Johnson reported first-quarter earnings of $2.71 per share, beating FactSet's consensus of $2.66.
Johnson & Johnson's (JNJ) talc-based baby powder did not cause cancer in a Florida woman, according to a recent jury verdict.
Johnson & Johnson's talc-based baby powder was not the cause of a woman's death from ovarian cancer, a Florida jury decided in a case brought against the manufacturer. Separately, Eli Lilly warned ...
The complaint alleged that Pat Matthey's cancer was linked to the talc-based baby powder produced by Johnson & Johnson. A ...
A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a ...
There have been varied opinions from researchers and government agencies if talc-based powders increase the risk of ovarian ...
Johnson & Johnson reported mixed first-quarter results on Tuesday, with adjusted earnings surpassing Wall Street's ...
Johnson & Johnson's first-quarter revenue missed Wall Street estimates for medical devices on Tuesday and sales of its ...
The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures ...